Hemostemix Inc.
HMTXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $1 | $0 |
| G&A Expenses | $1 | $1 | $3 | $6 |
| SG&A Expenses | $2 | $2 | $4 | $6 |
| Sales & Mktg Exp. | $1 | $1 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$1 | $0 |
| Operating Expenses | $2 | $2 | $3 | $7 |
| Operating Income | -$2 | -$2 | -$3 | -$7 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$1 | -$0 | -$1 | $0 |
| Pre-Tax Income | -$3 | -$3 | -$5 | -$7 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$3 | -$3 | -$5 | -$6 |
| % Margin | – | – | – | – |
| EPS | -0.028 | -0.03 | -0.075 | -0.11 |
| % Growth | 9.2% | 59.5% | 32% | – |
| EPS Diluted | -0.028 | -0.03 | -0.075 | -0.11 |
| Weighted Avg Shares Out | 93 | 83 | 70 | 57 |
| Weighted Avg Shares Out Dil | 95 | 82 | 70 | 57 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$2 | -$2 | -$3 | -$3 |
| % Margin | – | – | – | – |